Join Now

Early-Phase Data Support Novel Contrast Agent

By Natalie Themm | Published July 1, 2026

ASE 2026 data support further development of MVT-100 in pivotal trials.

Posted in BioUtah News | Tagged | Comments Off on Early-Phase Data Support Novel Contrast Agent

New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation

By Natalie Themm | Published November 13, 2025

Salt Lake City, UT –Wednesday November, 5th 2025— Researchers from the University of Utah and Microvascular Therapeutics (MVT) will be presenting new preclinical data demonstrating that focused ultrasound (FUS) using proprietary phase-shift microbubbles, NanoBlate (MVT-101), can selectively ablate brain tumors and open the blood-brain barrier (BBB) in targeted regions, potentially enabling safer, more precise, and […]

Posted in BioUtah News | Tagged | Comments Off on New Preclinical Study Demonstrates Feasibility of Microbubble-Mediated, Non-Thermal Focused Ultrasound for Brain Tumor Ablation

Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

By Natalie Themm | Published July 17, 2025

Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

Posted in BioUtah News | Tagged | Comments Off on Microvascular Therapeutics Celebrates Major Achievements at ASE 2025 Scientific Sessions

Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

By Natalie Themm | Published June 19, 2025

Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

Posted in BioUtah News | Tagged | Comments Off on Microvascular Therapeutics announces Founder and CEO Dr. Evan Unger as panelist in Commercializing SBIR/STTR Technologies Discussion at BIO 2025

A Special Thanks To Our Legacy and Platinum Elite Members